About US
Contact us
-
In new lawsuit, J&J's talc subsidiary takes issue with expert witness testimonyAs the seasons change and one year turns to the next, Johnson & Johnson’s talcum powder litigation rolls on. In the latest twist, J&J is taking issue with testimony from an expert witness2022/12/21
-
Xeris gets green light to take subcutaneous challenger to AbbVie drug into phase 2Xeris Biopharma has the green light to take its subcutaneous levothyroxine into phase 2. After talking to the FDA, the companyoutlinedplans to start a midphase trial of the investigational alternativ2022/12/21
-
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancerIt’s been relatively smooth sailing for AstraZeneca and Merck’s Lynparza as it has gained indications in ovarian, breast, pancreatic and prostate cancer. But on Thursday, the companies reported a2022/12/19
-
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts accessIt's no secret that drugmakers will do whatever it takes to defend their products from generics for as long as possible. Now, nine drugmakers are being asked to reconsider their patenting strategies.2022/12/19
-
ASH: Amgen's Blincyto looks to establish new leukemia standard after 9-year trialA clinical trial that started before the first FDA approval for Blincyto might support a new use for the Amgen therapy in acute lymphoblastic leukemia (ALL). Blincyto helped patients with newly di2022/12/14
-
Sanofi started—and lost—$28B bidding war for Horizon. Is the company's M&A appetite still rumbling?Sanofi may have backed down against Amgen in a recent M&A bidding war, but its initial offer that got the ball rolling on the $28 billion buyout of Horizon Therapeutics suggests the French Pharma2022/12/14
-
Arcutis' topical cream goes 2 for 2 in pivotal eczema trials to clear path to FDAArcutis Biotherapeutics’ topical cream hasracked upa second phase 3 win in eczema patients, putting the company on track to file for FDA approval in the indication in the second half of next year.2022/12/12
-
UPDATED: As Novo irons out obesity supply wrinkles, blockbuster-to-be Wegovy debuts in EuropeLooking to avoid another false start for its obesity blockbuster-in-waiting Wegovy, Novo Nordisk isn’t rushing the launch of its semaglutide med in Europe. The GLP-1 drug was originally set to deb2022/12/12
-
Re-Vana reels in $12M to develop sustained-release eye implantsInvestors haveboostedRe-Vana Therapeutics’ ambition to develop sustained-release eye disease drugs, putting up $11.9 million in series A funding on the back of nonclinical ocular safety and efficacy2022/12/7
-
Vaxxas raises $23M to fund needle-free COVID-19 vaccine trialVaxxas hassecuredfunding to support clinical development of its needle-free COVID-19 vaccine, stuffing its coffers with $23 million from investors including OneVentures and UniQuest. The2022/12/7